ESMO 2022 | Using pharmacokinetic and pharmacodynamic triggered approaches to study glioblastoma therapies

Nader Sanai, MD, Barrow Neurological Institute, Phoenix, AZ, discusses the limitations presented by tissue-based approaches to investigate glioblastoma. More pharmacokinetic and pharmacodynamic triggered approaches in Phase 0 trials and hybrid studies are being used to analyse drug effects in patients in real-time and derive conclusions. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.